Skip to main content
Genome&Company logo

Genome&Company — Investor Relations & Filings

Ticker · 314130 ISIN · KR7314130006 KO Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2020-07-08 Major Shareholding Noti…
Country KR South Korea
Listing KO 314130

About Genome&Company

http://genomecom.co.kr/

Genome&Company is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics. The company's research and development pipeline is centered on two primary platforms: microbiome-based pharmaceuticals and novel immune checkpoint inhibitors for immuno-oncology. Its drug candidates are derived from its proprietary microbiome platform and are aimed at treating a range of diseases, with a significant focus on cancer. In addition to its pharmaceutical programs, the company develops and markets consumer healthcare products, including dietary supplements and cosmeceuticals, leveraging its expertise in microbes and probiotics.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Supervisory Service in South Korea. It details changes in share ownership by major shareholders and special related parties, including specific transaction dates, share counts, and the purpose of holding (management influence). This type of filing is a standard regulatory disclosure regarding significant ownership thresholds, which falls under the 'Major Shareholding Notification' category.
2020-07-08 Korean
증권발행결과(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the results of a securities issuance (specifically a third-party allocated paid-in capital increase). It details the number of shares issued, the amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2020-06-25 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a decision for a third-party paid-in capital increase (유상증자결정) by Genome & Company. This type of filing is a formal regulatory disclosure in the Korean market concerning changes in capital structure, specifically the issuance of new shares. According to the provided definitions, this falls under 'Share Issue/Capital Change' (SHA).
2020-06-17 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties, including specific transaction dates and reasons (e.g., stock option exercises). This falls under the category of Major Shareholding Notification.
2020-05-12 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. This document details the share ownership and changes in holdings (specifically stock option exercises) by an executive (Yoon Kyung-wan) of Genome & Company. In the context of financial filings, reports detailing personal share transactions by company directors and executives are classified as 'Director's Dealing'.
2020-05-12 Korean
증권발행결과(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Securities Issuance Result' (증권 발행결과) announcement from Genome & Company. It details the final results of a third-party capital increase (유상증자) including the number of shares issued, the amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2020-04-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.